Blood Cancer

Latest News

Duvelisib Shows Promise in Treating Relapsed/Refractory CLL/SLL: Insights from the DUO Trial
Duvelisib Shows Promise in Treating Relapsed/Refractory CLL/SLL: Insights from the DUO Trial

June 17th 2024

The recent DUO trial, a global Phase III study, compared the efficacy and safety of duvelisib, an oral PI3K inhibitor, with ofatumumab, an anti-CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had previously undergone at least one therapy.

Could Tattoos Increase Risk of Malignant Lymphoma?
Could Tattoos Increase Risk of Malignant Lymphoma?

June 10th 2024

The Role of Pharmacogenomics in Reducing Racial Disparities in Pediatric AML Treatment Outcomes
The Role of Pharmacogenomics in Reducing Racial Disparities in Pediatric AML Treatment Outcomes

May 20th 2024

New Study Confirms Economic Burden of Chronic Lymphocytic Leukemia on Medicare Beneficiaries
New Study Confirms Economic Burden of Chronic Lymphocytic Leukemia on Medicare Beneficiaries

May 16th 2024

Daratumumab Therapy Effective for Newly Diagnosed High-Risk Multiple Myeloma
Daratumumab Therapy Effective for Newly Diagnosed High-Risk Multiple Myeloma

May 7th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.